To determine whether CD99 activation can disrupt EGF-induced dimerization and activation of EGFR, two breast cancer cell lines, MDA-MB-231 and MCF-7, were treated with CD99 agonist ligands, CD99CRIII3 or CD99-Fc. This evidence concerns the gene EGFR and breast carcinoma.